WallStreetZenWallStreetZen

NASDAQ: BEAT
Heartbeam Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for BEAT

Based on 1 analyst offering 12 month price targets for Heartbeam Inc.
Min Forecast
$9.00+343.35%
Avg Forecast
$9.00+343.35%
Max Forecast
$9.00+343.35%

Should I buy or sell BEAT stock?

Based on 1 analyst offering ratings for Heartbeam Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BEAT stock forecasts and price targets.

BEAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Benchmark
Top 5%
96
BuyInitiates Coverage On$9.00+343.35%2021-12-20

1 of 1

Forecast return on equity

Is BEAT forecast to generate an efficient return?
Company
110.56%
Industry
11.97%
Market
118.57%
BEAT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BEAT forecast to generate an efficient return on assets?
Company
101.81%
Industry
8.18%
BEAT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BEAT earnings per share forecast

What is BEAT's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.88
Avg 2 year Forecast
-$0.33
Avg 3 year Forecast
-$0.06

BEAT revenue forecast

What is BEAT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$16.7M
Avg 2 year Forecast
$96.3M
Avg 3 year Forecast
$210.4M

BEAT vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
BEAT$2.03$9.00+343.35%Buy
HCTI$0.40$4.00+895.02%Strong Buy
KERN$0.11$3.08+2,828.57%Hold
UTRS$0.84$9.00+966.35%Buy
WORX$0.68N/AN/A

Heartbeam Stock Forecast FAQ

Is Heartbeam Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BEAT) stock is to Buy BEAT stock.

Out of 1 analyst, 0 (0%) are recommending BEAT as a Strong Buy, 1 (100%) are recommending BEAT as a Buy, 0 (0%) are recommending BEAT as a Hold, 0 (0%) are recommending BEAT as a Sell, and 0 (0%) are recommending BEAT as a Strong Sell.

If you're new to stock investing, here's how to buy Heartbeam stock.

What is BEAT's earnings growth forecast for 2022-2024?

(NASDAQ: BEAT) Heartbeam's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 7.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Heartbeam's earnings in 2022 is -$8,944,000.On average, 1 Wall Street analyst forecast BEAT's earnings for 2022 to be -$7,036,267, with the lowest BEAT earnings forecast at -$7,036,267, and the highest BEAT earnings forecast at -$7,036,267. On average, 1 Wall Street analyst forecast BEAT's earnings for 2023 to be -$2,638,600, with the lowest BEAT earnings forecast at -$2,638,600, and the highest BEAT earnings forecast at -$2,638,600.

In 2024, BEAT is forecast to generate -$479,745 in earnings, with the lowest earnings forecast at -$479,745 and the highest earnings forecast at -$479,745.

What is BEAT's revenue growth forecast for 2024-2026?

(NASDAQ: BEAT) Heartbeam's forecast annual revenue growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 14.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Heartbeam's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast BEAT's revenue for 2024 to be $133,529,159, with the lowest BEAT revenue forecast at $133,529,159, and the highest BEAT revenue forecast at $133,529,159. On average, 1 Wall Street analysts forecast BEAT's revenue for 2025 to be $769,751,623, with the lowest BEAT revenue forecast at $769,751,623, and the highest BEAT revenue forecast at $769,751,623.

In 2026, BEAT is forecast to generate $1,682,147,568 in revenue, with the lowest revenue forecast at $1,682,147,568 and the highest revenue forecast at $1,682,147,568.

What is BEAT's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: BEAT) forecast ROA is 101.81%, which is higher than the forecast US Health Information Services industry average of 8.18%.

What is BEAT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BEAT price target, the average BEAT price target is $9.00, with the highest BEAT stock price forecast at $9.00 and the lowest BEAT stock price forecast at $9.00.

The Wall Street analyst predicted that Heartbeam's share price could reach $9.00 by Dec 20, 2022. The average Heartbeam stock price prediction forecasts a potential upside of 343.35% from the current BEAT share price of $2.03.

What is BEAT's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: BEAT) Heartbeam's current Earnings Per Share (EPS) is -$1.42. On average, analysts forecast that BEAT's EPS will be -$0.88 for 2022, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.88. On average, analysts forecast that BEAT's EPS will be -$0.33 for 2023, with the lowest EPS forecast at -$0.33, and the highest EPS forecast at -$0.33. In 2024, BEAT's EPS is forecast to hit -$0.06 (min: -$0.06, max: -$0.06).

What is BEAT's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: BEAT) forecast ROE is 110.56%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.